PE20190439A1 - Derivados de carbonucleosidos sustituidos utiles como agentes antineoplasicos - Google Patents
Derivados de carbonucleosidos sustituidos utiles como agentes antineoplasicosInfo
- Publication number
- PE20190439A1 PE20190439A1 PE2018003140A PE2018003140A PE20190439A1 PE 20190439 A1 PE20190439 A1 PE 20190439A1 PE 2018003140 A PE2018003140 A PE 2018003140A PE 2018003140 A PE2018003140 A PE 2018003140A PE 20190439 A1 PE20190439 A1 PE 20190439A1
- Authority
- PE
- Peru
- Prior art keywords
- absent
- compounds
- membered heteroaryl
- present
- carbonucleosid
- Prior art date
Links
- 229940034982 antineoplastic agent Drugs 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 229910052760 oxygen Inorganic materials 0.000 abstract 4
- 229910052717 sulfur Inorganic materials 0.000 abstract 4
- 229910052799 carbon Inorganic materials 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 230000002159 abnormal effect Effects 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 230000010261 cell growth Effects 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 125000006648 (C1-C8) haloalkyl group Chemical group 0.000 abstract 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229910052731 fluorine Chemical group 0.000 abstract 1
- 239000011737 fluorine Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/34—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring with cyano groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by unsaturated carbon chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/22—Nitrogen and oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
- C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
- Silicon Polymers (AREA)
Abstract
Se refiere a compuestos de la Formula (I), o una sal de estos aceptable desde el punto de vista farmaceutico, en donde R1 se selecciona del grupo que consiste en hidroxi, heteroarilo de 5-12 miembros, entre otros; R2 es hidrogeno, halogeno, entre otros; cada R8 esta ausente o se selecciona de forma independiente entre heteroarilo de 5-12 miembros, (C1-C8)haloalquilo, entre otros; cada R9 es hidrogeno o fluor (de forma independiente); D es O, S, entre otros; G es un (C5-C12)arilo o un sistema de anillos de heteroarilo de 5-12 miembros, fusionado a un sistema de anillos de (C3-C10)cicloalquilo o heterociclilo; Q esta ausente o es una porcion divalente seleccionada de O, S, NH y (C1-C8)alquileno; V es N o C (si Z esta presente); W es N o C; X es N o C (si Y esta presente); Y esta ausente, es N, O, S, entre otros; y Z esta ausente, es N, O, S entre otros; ademas de composiciones farmaceuticas que comprenden al menos un compuesto de la invencion (puede combinarse con uno o mas compuestos diferentes de la invencion) asociado a uno o mas excipientes o portadores farmaceuticamente aceptables (segun el modo de administracion, efecto del excipiente en la solubilidad y estabilidad, entre otros factores). Tambien se refiere a procesos de preparacion de los compuestos, usos de las composiciones farmaceuticas que comprenden estos compuestos, y metodos para el tratamiento del crecimiento celular anormal (como el cancer) en mamiferos. La presente invencion es util para el tratamiento del crecimiento celular anormal (como el cancer) en mamiferos.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662346226P | 2016-06-06 | 2016-06-06 | |
| US201662376856P | 2016-08-18 | 2016-08-18 | |
| US201662431714P | 2016-12-08 | 2016-12-08 | |
| US201762506076P | 2017-05-15 | 2017-05-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20190439A1 true PE20190439A1 (es) | 2019-03-27 |
Family
ID=59071035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018003140A PE20190439A1 (es) | 2016-06-06 | 2017-06-03 | Derivados de carbonucleosidos sustituidos utiles como agentes antineoplasicos |
Country Status (42)
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7328218B2 (ja) | 2017-10-26 | 2023-08-16 | プレリュード セラピューティクス，インコーポレイティド | タンパク質アルギニンメチルトランスフェラーゼ５（ｐｒｍｔ５）の選択的阻害剤 |
| CN111741964A (zh) * | 2017-12-05 | 2020-10-02 | 安杰斯制药公司 | 作为prmt5抑制剂的杂环化合物 |
| CN108997309A (zh) * | 2018-07-17 | 2018-12-14 | 中国科学技术大学苏州研究院 | 一种吡唑-4-芳基衍生物的制备方法 |
| WO2020033285A1 (en) * | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| WO2020152557A1 (en) * | 2019-01-23 | 2020-07-30 | Pfizer Inc. | Polymorph form of a monophosphate hydrate salt of a known tetrahydroisoquinoline derivative |
| AU2020256166A1 (en) * | 2019-04-02 | 2021-10-14 | Aligos Therapeutics, Inc. | Compounds targeting PRMT5 |
| JP2022534998A (ja) * | 2019-05-30 | 2022-08-04 | エンジェクス ファーマシューティカル インコーポレイテッド | Ｐｒｍｔ５阻害剤としての複素環式化合物 |
| CR20220010A (es) | 2019-06-10 | 2022-05-13 | Lupin Ltd | Inhibidores de prmt5 |
| BR112022006226A2 (pt) * | 2019-10-07 | 2022-06-28 | De Shaw Res Llc | Compostos heterocíclicos de arilmetileno como bloqueadores de canal do agitador de potássio kv1,3 |
| US20230066014A1 (en) * | 2019-12-03 | 2023-03-02 | Lupin Limited | Substituted nucleoside analogs as prmt5 inhibitors |
| KR20220101681A (ko) * | 2019-12-18 | 2022-07-19 | 화이자 인코포레이티드 | Prmt5 억제제를 사용한 1일 1회 암 치료 요법 |
| EP4087576A1 (en) * | 2020-01-07 | 2022-11-16 | Pfizer Inc. | Prmt5 inhibitor for use in a method of treating psoriasis and other autoimmune conditions |
| CN111138355A (zh) * | 2020-01-17 | 2020-05-12 | 成都睿智化学研究有限公司 | 一种甲醛取代的氮杂稠环类化合物的制备方法 |
| WO2021152055A1 (en) | 2020-01-31 | 2021-08-05 | Solvay Sa | Process for the manufacture of haloalkyl substituted pyridine compounds |
| US20220112194A1 (en) * | 2020-04-01 | 2022-04-14 | Aligos Therapeutics, Inc. | Compounds targeting prmt5 |
| WO2022013692A1 (en) | 2020-07-15 | 2022-01-20 | Pfizer Inc. | Polymorphs of (1s,2s,3s,5r)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7h-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol mono-hydrochloride |
| US20240116937A1 (en) | 2020-07-15 | 2024-04-11 | Pfizer Inc. | Polymorph of (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-D]pyrimidin-7-yl)cyclopentane-1,2-diol |
| WO2022153161A1 (en) | 2021-01-14 | 2022-07-21 | Pfizer Inc. | Treatment of cancer using a prmt5 inhibitor |
| CN113234079B (zh) * | 2021-04-30 | 2022-02-01 | 上海湃隆生物科技有限公司 | 用作prmt5抑制剂的核苷类似物 |
| WO2024118943A2 (en) * | 2022-11-30 | 2024-06-06 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a prmt5 inhibitor |
| WO2024170488A1 (en) | 2023-02-13 | 2024-08-22 | Astrazeneca Ab | Prmt5 inhibitor for use in cancer therapy |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026008533A1 (en) | 2024-07-01 | 2026-01-08 | Janssen Pharmaceutica Nv | Prmt5 inhibitors for treating adenomas |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US6143749A (en) * | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| EP1780201A3 (en) | 2001-02-22 | 2007-05-16 | Celltech R&D Limited | Phenylalanine enamide derivatives possessing a cyclobutene group, for use as integrin inhibitors |
| US20040043959A1 (en) * | 2002-03-04 | 2004-03-04 | Bloom Laura A. | Combination therapies for treating methylthioadenosine phosphorylase deficient cells |
| EP1987717A1 (de) | 2007-04-30 | 2008-11-05 | Bayer CropScience AG | Pyridoncarboxamide, diese enthaltende nutzpflanzenschützende Mittel und Verfahren zu ihrer Herstellung und deren Verwendung |
| WO2010100475A1 (en) | 2009-03-02 | 2010-09-10 | Astrazeneca Ab | Hydroxamic acid derivatives as gram-negative antibacterial agents |
| CA2820550C (en) * | 2010-12-02 | 2016-02-23 | Youai Co.,Ltd | Purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative with inhibitory activity against raf kinase |
| IN2012CH01573A (es) | 2012-04-20 | 2015-07-10 | Advinus Therapeutics Ltd | |
| HRP20182037T1 (hr) | 2012-12-21 | 2019-02-08 | Epizyme, Inc. | Inhibitori prmt5 i njihova uporaba |
| US20160168185A1 (en) | 2013-07-22 | 2016-06-16 | Baylor College Of Medicine | Non-ribose containing inhibitors of histone methyltransferase dot1l for cancer treatment |
| EP3160477A4 (en) | 2014-06-25 | 2018-07-04 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| JP6758308B2 (ja) * | 2015-02-25 | 2020-09-23 | アウトセンス ダイアグノスティクス リミテッド | 人体排泄物の解析 |
| TWI791251B (zh) | 2015-08-26 | 2023-02-01 | 比利時商健生藥品公司 | 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物 |
-
2017
- 2017-06-01 CA CA2969295A patent/CA2969295A1/en active Pending
- 2017-06-02 US US15/612,030 patent/US10220037B2/en active Active
- 2017-06-03 TN TNP/2018/000424A patent/TN2018000424A1/en unknown
- 2017-06-03 PL PL17730948T patent/PL3464249T3/pl unknown
- 2017-06-03 MA MA45153A patent/MA45153B1/fr unknown
- 2017-06-03 MD MDE20190422T patent/MD3464249T2/ro unknown
- 2017-06-03 HR HRP20211449TT patent/HRP20211449T1/hr unknown
- 2017-06-03 EP EP17730948.1A patent/EP3464249B1/en active Active
- 2017-06-03 SG SG11201810485SA patent/SG11201810485SA/en unknown
- 2017-06-03 ES ES17730948T patent/ES2890435T3/es active Active
- 2017-06-03 GE GEAP201714948A patent/GEP20217211B/en unknown
- 2017-06-03 CR CR20180578A patent/CR20180578A/es unknown
- 2017-06-03 WO PCT/IB2017/053295 patent/WO2017212385A1/en not_active Ceased
- 2017-06-03 MY MYPI2018002348A patent/MY196413A/en unknown
- 2017-06-03 CU CU2018000144A patent/CU24517B1/es unknown
- 2017-06-03 AU AU2017279014A patent/AU2017279014B2/en not_active Ceased
- 2017-06-03 DK DK17730948.1T patent/DK3464249T3/da active
- 2017-06-03 SG SG10202100861TA patent/SG10202100861TA/en unknown
- 2017-06-03 KR KR1020197000054A patent/KR102215313B1/ko not_active Expired - Fee Related
- 2017-06-03 JP JP2018563551A patent/JP6553825B2/ja not_active Expired - Fee Related
- 2017-06-03 RS RS20211156A patent/RS62351B1/sr unknown
- 2017-06-03 BR BR112018075166-9A patent/BR112018075166A2/pt not_active Application Discontinuation
- 2017-06-03 PE PE2018003140A patent/PE20190439A1/es unknown
- 2017-06-03 HU HUE17730948A patent/HUE056634T2/hu unknown
- 2017-06-03 LT LTEPPCT/IB2017/053295T patent/LT3464249T/lt unknown
- 2017-06-03 SI SI201730926T patent/SI3464249T1/sl unknown
- 2017-06-03 CN CN201780049070.8A patent/CN109890797B/zh not_active Expired - Fee Related
- 2017-06-03 MX MX2018015094A patent/MX384948B/es unknown
- 2017-06-03 UA UAA201812060A patent/UA124386C2/uk unknown
- 2017-06-03 PT PT177309481T patent/PT3464249T/pt unknown
- 2017-06-03 RU RU2018142734A patent/RU2712944C1/ru active
- 2017-06-03 KR KR1020217003681A patent/KR20210018529A/ko not_active Ceased
- 2017-06-05 TW TW107130452A patent/TWI667240B/zh not_active IP Right Cessation
- 2017-06-05 TW TW106118476A patent/TWI637945B/zh not_active IP Right Cessation
- 2017-06-05 UY UY0001037274A patent/UY37274A/es not_active Application Discontinuation
-
2018
- 2018-11-16 ZA ZA2018/07723A patent/ZA201807723B/en unknown
- 2018-11-29 PH PH12018502535A patent/PH12018502535B1/en unknown
- 2018-12-04 NI NI201800128A patent/NI201800128A/es unknown
- 2018-12-04 CO CONC2018/0013105A patent/CO2018013105A2/es unknown
- 2018-12-05 IL IL263505A patent/IL263505B/en active IP Right Grant
- 2018-12-06 EC ECSENADI201890743A patent/ECSP18090743A/es unknown
- 2018-12-06 SV SV2018005794A patent/SV2018005794A/es unknown
- 2018-12-06 DO DO2018000268A patent/DOP2018000268A/es unknown
- 2018-12-06 CL CL2018003504A patent/CL2018003504A1/es unknown
- 2018-12-18 US US16/224,016 patent/US10709709B2/en active Active
-
2019
- 2019-07-04 JP JP2019125220A patent/JP2019194231A/ja active Pending
- 2019-11-15 AU AU2019264640A patent/AU2019264640A1/en not_active Abandoned
-
2021
- 2021-04-08 IL IL282167A patent/IL282167A/en unknown
- 2021-09-16 CY CY20211100815T patent/CY1124798T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20190439A1 (es) | Derivados de carbonucleosidos sustituidos utiles como agentes antineoplasicos | |
| DOP2020000191A (es) | Derivados de 2-amino-piridina o 2-amino-pirimidina como inhibidores de cinasa dependientes de ciclina | |
| CY1124680T1 (el) | Παραγωγα 8-[6-[3-(αμινο)προποξυ]-3-πυριδυλο]-1-ισοπροπυλο-ιμιδαζο[4,5-c]κινολιν-2-ονης ως εκλεκτiκοι ρυθμιστες κινασης μεταλλαγμενης αταξιας τελαγγειεκτασιας (atm) για τη θεραπευτικη αγωγη του καρκινου | |
| MX2021010306A (es) | Gamma-carbolinas heterociclicas fusionadas sustituidas, composiciones farmaceuticas y metodos de uso. | |
| CU20190010A7 (es) | PIRIDO[2,3-d]PIRIMIDIN-7(8H)-ONAS 6-FLUOROALQUIL-2-(ALQUILSULFONILPIPERIDIN-4-IL)AMINO SUSTITUIDAS | |
| AR106037A1 (es) | Moduladores de la proteína core de la hepatitis b | |
| MX392572B (es) | Compuestos del péptido yy (pyy) selectivos y sus usos. | |
| ECSP22003665A (es) | Derivados de imidazo[4,5-c]piridina como agonistas del receptor tipo toll | |
| CL2018003492A1 (es) | Hepatitis b agentes antivirales. | |
| CL2018002549A1 (es) | Eliminación del virus de la hepatitis b con agentes antivirales | |
| ECSP23073404A (es) | 3,4-dihidro-2,7-naftiridin-1,6(2h,7h)-dionas como inhibidores de mek | |
| PE20190910A1 (es) | Compuestos terapeuticos utiles para el tratamiento profilactico o terapeutico de una infeccion por el virus del vih | |
| CL2017001426A1 (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. | |
| CO2018009559A2 (es) | Derivados de indol sustituidos como inhibidores de la replicación vírica del dengue | |
| UY38471A (es) | Compuestos de azalactam como inhibidores de hpk1 | |
| CL2018002784A1 (es) | Derivados de compuestos de indol sustituidos como inhibidores de la replicación vírica del dengue. | |
| ATE536172T1 (de) | Ezetimibzusammensetzungen | |
| CL2019001023A1 (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia. | |
| CU24608B1 (es) | Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas y métodos para preparar dichos compuestos | |
| UY29301A1 (es) | Derivados amida | |
| PE20211246A1 (es) | Compuestos biciclicos para su uso como inhibidores de rip1 quinasa | |
| PE20181447A1 (es) | Derivados de eter ciclico de pirazolo[1,5-a]pirimidin-3-carboxiamida | |
| CO2017011969A2 (es) | Derivados de imidazo[1,2-b][1,2,4]triazina como agentes antiparasitarios | |
| ECSP19084722A (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
| PL420169A1 (pl) | N-Guanylowe pochodne 9-amino-5,11-dimetylo-5H-indolo[2,3-b]chinoliny, sposób ich otrzymywania i zawierające je środki farmaceutyczne |